Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomakers in a drug-sensitive tumor, testicular cancer

Neoplasia

Volumn 10, Issue 10, 2008, Pages 1041-1048

  De Haas, Esther C ^a   Di Pietro, Alessandra ^a   Simpson, Kathryn L ^b   Meijer, Coby ^a   Suurmeijer, Albert J H ^a   Lancashire, Lee J ^b   Cummings, J ^b   De Jong, Steven ^a   De Vries, Elisabeth G E ^a   Dive, Caroline ^b   Gietema, Jourik A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTIGEN; BLEOMYCIN; CASPASE CLEAVED CYTOKERATIN 18; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYTOKERATIN 18; ETOPOSIDE; LACTATE DEHYDROGENASE; M30 ANTIGEN; M65 ANTIGEN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TESTIS CANCER;

EID: 54249157397     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08620     Document Type: Article

References (32)

1. Collins I and Workman P (2006). New approaches to molecular cancer therapeutics. Nat Chem Biol 2, 689-700.
2. Kummar S, Gutierrez M, Doroshow JH, and Murgo AJ (2006). Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 62, 15-26.
3. Ludwig JA and Weinstein JN (2005). Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5, 845-856.
4. Maruvada P and Srivastava S (2006). Joint National Cancer Institute-Food and Drug Administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection. Cancer Epidemiol Biomarkers Prev 15, 1078-1082.
5. Cummings J, Ward TH, Greystoke A, Ranson M, and Dive C (2008). Biomarker method validation in anticancer drug development. Br J Pharmacol 153, 646-656.
6. Bivén K, Erdal H, Hägg M, Ueno T, Zhou R, Lynch M, Rowley B, Wood J, Zhang C, Toi M, et al. (2003). A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 8, 263-268.
7. Hägg M, Bivén K, Ueno T, Rydlander L, Björklund P, Wiman KG, Shoshan M, and Linder S (2002). A novel high-through-put assay for screening of proapoptotic drugs. Invest New Drugs 20, 253-259.
8. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, Marberger M, Bivén K, Shoshan MC, and Linder S (2004). Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64, 1751-1756.
9. Ku NO, Liao J, and Omary MB (1997). Apoptosis generates stable fragments of human type I keratins. J Biol Chem 272, 33197-33203.
10. Leers MP, Kölgen W, Björklund V, Bergman T, Tribbick G, Persson B, Björklund P, Ramaekers FC, Björklund B, Nap M, et al. (1999). Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187, 567-572.
11. Schutte B, Henfling M, Kölgen W, Bouman M, Meex S, Leers MP, Nap M, Björklund V, Björklund P, Björklund B, et al. (2004). Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 297, 11-26.
12. Cummings J, Ranson M, Butt F, Moore D, and Dive C (2007). Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother Pharmacol 60, 921-924.
13. Cummings J, Ranson M, Lacasse E, Ganganagari JR, St-Jean M, Jayson G, Durkin J, and Dive C (2006). Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 95, 42-48.
14. Cummings J, Ward TH, LaCasse E, Lefebvre C, St-Jean M, Durkin J, Ranson M, and Dive C (2005). Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 92, 532-538.
15. Greystoke A, Cummings J, Ward T, Simpson K, Renehan A, Butt F, Moore D, Gietema J, Blackhall F, Ranson M, et al. (2008). Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol 19, 990-995.
16. Demiray M, Ulukaya EE, Arslan M, Gokgoz S, Saraydaroglu O, Ercan I, Evrensel T, and Manavoglu O (2006). Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest 24, 669-676.
17. Kramer G, Schwarz S, Hägg M, Havelka AM, and Linder S (2006). Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 94, 1592-1598.
18. Ueno T, Toi M, Bivén K, Bando H, Ogawa T, and Linder S (2003). Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 39, 769-774.
19. Ulukaya E, Yilmaztepe A, Akgoz S, Linder S, and Karadag M (2007). The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 56, 399-404.
20. Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, and Pisters LL (2006). Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 107, 1483-1490.
21. Inanç SE, Meral R, Darendeliler E, Yasasever V, and Onat H (1999). Prognostic significance of marker half-life during chemotherapy in nonseminomatous germ cell testicular tumors. Acta Oncol 38, 505-509.
22. Morelli F, Tozzi L, Setola P, Bisceglia M, Barbini VR, and Maiello E (2006). Postchemotherapy residual masses in germ cell tumor patients: our experience. Ann Oncol 17, vii132-vii136.
23. Oldenburg J, Alfsen GC, Lien HH, Aass N, Waehre H, and Fossa SD (2003). Postchemotherapy retroperitoneal surgery remains necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses. J Clin Oncol 21, 3310-3317.
24. Huddart RA and Purkalne G (2005). ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of mixed or nonseminomatous germ cell tumors (NSGCT). Ann Oncol 16, i37-i39.
25. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, et al. (2004). European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15, 1377-1399.
26. de Wit R, Collette L, Sylvester R, de Mulder PH, Sleijfer DT, ten Bokkel Huinink WW, Kaye SB, van Oosterom AT, Boven E, and Stoter G (1998). Serum alpha-fetoprotein surge after the initiation of chemotherapy for nonseminomatous testicular cancer has an adverse prognostic significance. Br J Cancer 78, 1350-1355.
27. Hann J and Kamber M (2000). Data Preprocessing in Data Mining: Concepts and Techniques. San Francisco, CA: Morgan Kaufmann, pp. 105-145.
28. van Dalen A (1996). Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease. Anticancer Res 16, 2345-2349.
29. Cheville JC, Rao S, Iczkowski KA, Lohse CM, and Pankratz VS (2000). Cytokeratin expression in seminoma of the human testis. Am J Clin Pathol 113, 583-588.
30. Feitz WF, Debruyne FM, and Ramaekers FC (1987). Intermediate filament proteins as tissue specific markers in normal and neoplastic testicular tissue. Int J Androl 10, 51-56.
31. Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, et al. (2007). Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 13, 3198-3206.
32. Adlbrecht C, Hoetzenecker K, Posch M, Steiner S, Kopp C, Hacker S, Auer J, Horvath R, Moser B, Roth G, et al. (2007). Elevated levels of interleukin-1beta-converting enzyme and caspase-cleaved cytokeratin-18 in acute myocardial infarction. Eur J Clin Invest 37, 372-380.